Micro-anatomical variation in cellular proliferation in endometrial adenocarcinoma, and inverse correlation between Ki67 and cytokeratin 7 expression

Histopathology

Volumn 57, Issue 1, 2010, Pages 46-54

  Stewart, Colin J R ^a   Crook, Maxine L ^a   Doherty, Dorota A ^b  

^a King Edward Memorial Hospital   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

carcinoma; endometrium; immunohistochemistry; MELF; proliferation

Indexed keywords

CYTOKERATIN 7; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; EPITHELIUM; EXOCRINE GLAND; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR INVASION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954545658     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03588.x     Document Type: Article

References (52)

1. Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005 366 491 505.
2. Sorosky JI. Endometrial cancer. Obstet. Gynecol. 2008 111 436 447.
3. Prat J. Prognostic parameters of endometrial carcinoma. Hum. Pathol. 2004 35 649 662.
4. Mannelqvist M, Stefansson I, Salvesen HB, Akslen LA. Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology 2009 54 174 183.
5. Ambros RA, Ballouk F, Malfetano JH, Ross JS. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am. J. Surg. Pathol. 1994 18 569 575.
6. Moberger B, Auer G, Einhorn N, Moberger G. The prognostic significance of growth pattern and its relation to tumor cell nuclear DNA content in endometrial carcinoma. Acta Oncol. 1990 29 17 23.
7. Mittal KR, Barwick KW. Diffusely infiltrating adenocarcinoma of the endometrium. A subtype with poor prognosis. Am. J. Surg. Pathol. 1988 12 754 758.
8. Lee KR, Vacek PM, Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol. Oncol. 1994 54 10 18.
9. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004 44 472 479.
10. Longacre T, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am. J. Surg. Pathol. 1999 23 69 78.
11. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int. J. Gynecol. Pathol. 2003 22 324 333.
12. Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int. J. Gynecol. Pathol. 2007 26 115 123.
13. Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum. Pathol. 2008 39 116 125.
14. Stewart CJR, Brennan BA, Leung YC, Little L. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009 41 454 459.
15. Stewart CJR, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 2009 55 91 101.
16. Stewart CJ, Crook ML, Leung YC, Platten M. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod. Pathol. 2009 22 725 733.
17. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007 39 305 318.
18. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002 2 442 454.
19. Hugo H, Ackland ML, Blick T et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 2007 213 374 383.
20. Prall P. Tumour budding in colorectal carcinoma. Histopathology 2007 50 151 162.
21. Palmqvist R, Rutegard JN, Bozoky B, Landberg G, Stenling R. Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am. J. Pathol. 2000 157 1947 1953.
22. INK4A and is a region of low proliferation. Am. J. Pathol. 2001 159 1613 1617.
23. ink4a and the proliferative activity of different areas' tumour cells in human colorectal cancer. Int. J. Clin. Pract. 2007 61 1523 1529.
24. Rubio CA. Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report. Anticancer Res. 2008 28 2417 2420.
25. Palmqvist R, Sellberg P, Oberg A et al. Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br. J. Cancer 1999 79 577 581.
26. Rubio CA. Morphologic and molecular events at the invading edge of colorectal carcinomas. Int. J. Clin. Exp. Pathol. 2008 1 98 104.
27. Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int. J. Gynecol. Pathol. 2006 25 52 58.
28. Michalides RJAM. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J. Clin. Pathol. 1999 52 555 568.
29. Abal M, Planaguma J, Gil-Moreno A et al. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol. Histopathol. 2006 21 197 204.
30. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS 2002 110 673 689.
31. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 2006 29 4783 4791.
32. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J. Clin. Pathol. 2008 61 36 42.
33. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin. Cancer Biol. 2004 14 105 114.
34. Fodde R, Brabletz T. Wnt/β-catenin signalling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007 19 150 158.
35. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002 40 2 11.
36. Zergeroglu S, Ozdemir HB, Ozel M, Kuzey GM, Mollamahmutoglu L. The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas. J. Obstet. Gynaecol. 2006 26 798 801.
37. Bonatz G, Luttges J, Hedderich J et al. Prognostic significance of a novel proliferation marker, anti-repp 86, for endometrial carcinoma: a multivariate study. Hum. Pathol. 1999 30 949 956.
38. Cherchi PL, Marras V, Capobianco G et al. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 2001 22 451 453.
39. Al Kushi A, Lim P, Aquino-Parsons C, Blake CB. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod. Pathol. 2002 15 65 71.
40. Shih H-C, Shiozawa T, Kato K et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum. Pathol. 2003 34 471 478.
41. Ferrandina G, Ranelletti FO, Gallotta V et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol. Oncol. 2005 98 383 389.
42. INK4A in human endometrial adenocarcinoma. Exp. Oncol. 2006 28 152 155.
43. Nordstrom B, Strang B, Bergstrom R, Nilsson S, Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer 1996 78 1942 1951.
44. Kallakury BVS, Ambros RA, Hayner-Buchan AM, Sheehan CE, Malfetano JH, Ross JS. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int. J. Gynecol. Pathol. 1998 17 320 326.
45. Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin. Cancer Res. 1998 4 2779 2785.
46. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol. Oncol. 1999 75 432 436.
47. Salvesen HB, Iversen OE, Asklen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J. Clin. Oncol. 1999 17 1382 1390.
48. Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol. Oncol. 2004 93 34 40.
49. Horree N, van Diest PJ, Sie-Go DMDS, Heintz APM. The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum. Pathol. 2007 38 1232 1238.
50. Semczuk A, Skomra D, Cybulski M et al. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem. J. 2001 33 193 200.
51. Svensson S, Nilsson K, Ringberg A, Landberg G. Invade or proliferate? Two contrasting events in malignant behavior governed by p16INK4A and an intact Rb pathway illustrated by a model system of basal cell carcinoma Cancer Res. 2003 63 1737 1742.
52. Liu X-P, Oga A, Suehiro Y, Furuya T, Kawauchi S, Sasaki K. Inverse relationship between matrilysin expression and proliferative activity of cells in advanced gastric carcinoma. Hum. Pathol. 2002 33 741 747.